Evaluating the administration costs of biologic drugs: development of a cost algorithm
Tóm tắt
Biologic drugs, as with all other medical technologies, are subject to a number of regulatory, marketing, reimbursement (financing) and other demand-restricting hurdles applied by healthcare payers. One example is the routine use of cost-effectiveness analyses or health technology assessments to determine which medical technologies offer value-for-money. The manner in which these assessments are conducted suggests that, holding all else equal, the economic value of biologic drugs may be determined by how much is spent on administering these drugs or trade-offs between drug acquisition and administration costs. Yet, on the supply-side, it seems very little attention is given to how manufacturing and formulation choices affect healthcare delivery costs. This paper evaluates variations in the administration costs of biologic drugs, taking care to ensure consistent inclusion of all relevant cost resources. From this, it develops a regression-based algorithm with which manufacturers could possibly predict, during process development, how their manufacturing and formulation choices may impact on the healthcare delivery costs of their products.
Tài liệu tham khảo
Danzon PM, Wang YR, Wang L: The impact of price regulation on the launch delay of new drug - evidence from twenty-five major markets in the 1990s. Health Econ 2005, 14(3):269–292. 10.1002/hec.931
Cheng MM, Alfonso R, Best JH, Garrison LP, Bruhn D, Veenstra DL: The economic value of reducing medication dosing frequency with drug delivery technologies: an evidence assessment. J Med Econ 2010, 13(2):193–202. 10.3111/13696991003757500
Tetteh E, Morris S: Systematic review of drug administration costs and implications for biopharmaceutical manufacturing. Appl Health Econ Health Policy 2013, 1–12.
Dranove D: Measuring costs. In Valuing health care: Costs, benefits, and effectiveness of pharmaceuticals and other medical technologies. Edited by: Sloan FA. Cambridge University Press, New York; 1995:61–75. 10.1017/CBO9780511625817.004
Arrow KJ: Uncertainty and the welfare economics of medical care. Am Econ Rev 1963, 53(5):941–973.
Dardanoni V, Wagstaff A: Uncertainty and the demand for medical care. J Health Econ 1990, 9(1):23. 10.1016/0167-6296(90)90039-6
Nixon RM, Thompson SG: Parametric modelling of cost data in medical studies. Statist Med 2004, 23(8):1311–1331. 10.1002/sim.1744
Briggs AH, Claxton K, Sculpher MJ: Decision modelling for health economic evaluation. Oxford University Press, New York; 2006.
Duan N: Smearing estimate: a nonparametric retransformation method. J Am Stat Assoc 1983, 78(383):605–610. 10.1080/01621459.1983.10478017
Manning W: The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ 1998, 17(3):283–295. 10.1016/S0167-6296(98)00025-3
Manning WG, Mullahy J: Estimating log models: to transform or not to transform? J Health Econ 2001, 20(4):461–494. 10.1016/S0167-6296(01)00086-8
Wooldridge JM: Introductory econometrics: a modern approach. Cengage Learning, Michigan; 2012.
Barber J, Thompson S: Multiple regression of cost data: use of generalised linear models. J Health Serv Res Policy 2004, 9(4):197–204. 10.1258/1355819042250249
Moran JL, Solomon PJ, Peisach AR, Martin J: New models for old questions: generalized linear models for cost prediction. J Eval Clin Pract 2007, 13(3):381–389. 10.1111/j.1365-2753.2006.00711.x
Manning WG, Basu A, Mullahy J: Generalized modeling approaches to risk adjustment of skewed outcomes data. J Health Econ 2005, 24(3):465–488. 10.1016/j.jhealeco.2004.09.011
Basu A, Rathouz PJ: Estimating marginal and incremental effects on health outcomes using flexible link and variance function models. Biostatistics 2005, 6(1):93–109. 10.1093/biostatistics/kxh020
Basu A: Extended generalized linear models: simultaneous estimation of flexible link and variance functions. Stata J 2005, 5(4):501.
Kennedy PE: Estimation with correctly interpreted dummy variables in semilogarithmic equations. Am Econ Rev 1981, 71(4):801.
Jan Van Garderen K, Shah C: Exact interpretation of dummy variables in semilogarithmic equations. Econometr J 2002, 5(1):149–159. 10.1111/1368-423X.00078
Bittner B, Richter W, Hourcade-Potelleret F, McIntyre C, Herting F, Zepeda M, Schmidt J: Development of a subcutaneous formulation for trastuzumab - nonclinical and clinical bridging approach to the approved intravenous dosing regimen. Arzneimittelforschung 2012, 62(09):401–409. 10.1055/s-0032-1321831
Wynne C, Harvey V, Schwabe C, Waaka D, McIntyre C, Bittner B: Comparison of subcutaneous and intravenous administration of trastuzumab: a phase i/ib trial in healthy male volunteers and patients with HER2-positive breast cancer. J Clin Pharmacol 2013, 53(2):192–201. 10.1177/0091270012436560
Samanta K, Moore L, Jones G, Evason J, Owen G: PCN39 Potential time and cost savings with herceptin (Trastuzumab) subcutaneous (SC) injection versus herceptin intravenous (IV) infusion: results from three different english patient settings. Value Health 2012, 15(7):A415. 10.1016/j.jval.2012.08.1232
De Cock E, Tao S, Urspruch A, Knoop A: RU2 Potential time savings with trastuzumab subcutaneous (SC) injection versus trastuzumab intravenous (IV) infusion: results from interviews conducted as part of a time-and-motion Study (T&M) across 17 sites. Value Health 2012, 15(7):A280. 10.1016/j.jval.2012.08.489
De La Horrie GF: Making biologic drugs more affordable. Drug discovery and development magazine. 8–10–2013. 8–10–2013. Ref Type: Online Source.
Eisenstein M: Something new under the skin. Nat Biotechnol 2011, 29(2):107–109. 10.1038/nbt.1768
Parker SE: Pharmacoeconomics of intravenous drug administration. Pharmacoeconomics 1992, 1(2):103–115. 10.2165/00019053-199201020-00007
Dychter SS: Subcutaneous drug delivery: a route to increased safety, patient satisfaction, and reduced costs. Infus Nurs 2012, 35(3):154. 10.1097/NAN.0b013e31824d2271
Chess R: Economics of drug delivery. Pharm Res 1998, 15(2):172–174. 10.1023/A:1011993913566